These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6393886)

  • 1. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo.
    Herrmann KS
    Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet aggregation in arterioles of the hamster cheek pouch and in heart transplants: its tissue-dependent influencibility by acetylsalicylic acid and nafazatrom.
    Herrmann KS; Seuter F
    Haemostasis; 1984; 14(3):281-7. PubMed ID: 6381254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.
    Weithmann KU; Just M; Schlotte V; Seiffge D
    Vasa; 1989; 18(4):273-6. PubMed ID: 2514520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.
    Hermán F; Hadházy P; Magyar K
    Arch Int Pharmacodyn Ther; 1989; 300():281-91. PubMed ID: 2482710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic efficacy and its time course after application of naftidrofuryl in vivo.
    Herrmann KS; Grosse-Heitmeyer A; Kreuzer H
    Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):145-54. PubMed ID: 3827406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.
    Buchanan MR; Butt RW; Turpie AG
    Am Heart J; 1987 May; 113(5):1133-7. PubMed ID: 2953219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrastructural observations of an electron dense amorphous layer on selectively damaged endothelial cells, a possible trigger of thrombogenesis in vivo, and its inhibition by nafazatrom.
    Herrmann KS; Voigt WH
    Thromb Res; 1984 Nov; 36(3):205-15. PubMed ID: 6083613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
    Michel G; Seipp U
    Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of arterial PGI2 generation and platelet aggregation by aspirin in rabbits ex vivo.
    Basista M
    Pol J Pharmacol Pharm; 1982; 34(5-6):317-21. PubMed ID: 6821216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue.
    Fischer S; Struppler M; Weber PC
    Biochem Pharmacol; 1983 Jul; 32(14):2231-6. PubMed ID: 6688182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment.
    Buchanan MR; Dejana E; Gent M; Mustard JF; Hirsch J
    J Clin Invest; 1981 Feb; 67(2):503-8. PubMed ID: 7007438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitory effect of aspirin on human endothelial cells.
    Nordoy A; Svensson B; Schroeder C; Hoak JC
    Thromb Haemost; 1978 Aug; 40(1):103-10. PubMed ID: 364762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
    Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T
    Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.